Main menu For students For teachers Explore our subjects Student events & courses

Teaching Biology

In the News

Can kickstarting the Krebs cycle clear brain fog after cancer?

Bryn Williams

19th November 2026

Share this content:

When you finish a successful cancer treatment, life is meant to get back to normal. Then, months later, you walk into a room and forget why you're there, or you lose the thread halfway through a sentence.

This experience is known as "chemo brain" or "brain fog" and happens to between 15% and 25% of breast cancer survivors. Doctors have very few treatments for it, so a team at UCLA tried something unusual - they used a molecule from the Krebs cycle.

That molecule is oxaloacetate. In the mitochondrial matrix, the two-carbon acetyl group from acetyl coenzyme A joins four-carbon oxaloacetate to make six-carbon citrate. Over the rest of the cycle, citrate is decarboxylated and dehydrogenated, which reduces three NAD and one FAD, and one ATP is made by substrate-level phosphorylation. At the end, oxaloacetate is regenerated, ready to pick up the next acetyl group. The reduced NAD and FAD then pass electrons to the electron transport chain, where most of the cell's ATP is made by oxidative phosphorylation. If oxaloacetate runs short, acetyl groups have nothing to join and the whole cycle slows down.

Oxaloacetate may also help in a second way. Glutamate (an amino acid) is the brain's main excitatory neurotransmitter and is vital for learning and memory, but if too much builds up around synapses it over-stimulates neurones and can damage them. The researchers think inflammation caused by cancer and its treatment may disrupt both the brain's energy supply and its glutamate signalling, and that this could contribute to brain fog. In their paper they describe oxaloacetate as mopping up excess glutamate, reducing inflammation and supporting mitochondrial energy production, which is why they chose to test it.

The trial recruited 18 women, average age about 50, who had finished their main treatment for early-stage breast cancer one to five years earlier and had significant thinking problems. Most had had chemotherapy, and nearly 90% were still on hormone therapy. They took 500 mg of oxaloacetate twice a day for eight weeks. Sixteen recruits finished after two stopped for digestive reasons. All of them reported a clear improvement. On a questionnaire where the women rated their own thinking, their average score rose from 29.1 to 55.5, moving from the "impaired" range into the normal range. The women also reported less fatigue and better physical functioning and standard tests showed faster processing speed and better executive function.

It’s a promising start, but consider the design. There were only 18 participants, and every one of them knew they were taking the supplement. There was no placebo group, and the main measure was how the women themselves rated their thinking. People who expect to feel better often do, symptoms can ease naturally with time, and people often score better on a test the second time simply through practice. The team calls the results preliminary and they are to be followed up by a randomised, placebo-controlled trial and mouse studies are testing how oxaloacetate might actually work.

Read the article on Science Daily here

Original paper in JCO Oncology Advances here

Discussion Points:

  1. Oxaloacetate is regenerated at the end of every turn of the Krebs cycle. Why would a shortage of oxaloacetate reduce ATP production even when plenty of glucose is available? Think about what the acetyl group must combine with, and what reduced NAD and reduced FAD go on to do.
  2. The Why do neurones in the brain require such large amounts of ATP to function properly? Think about sodium-potassium pumps, active transport, resting potentials and the synthesis and reabsorption of neurotransmitters at synapses.
  3. All 16 women who finished the trial reported feeling better. Why can't we conclude that oxaloacetate caused the improvement, and how would you design the next trial? Think about placebo groups, randomisation, blinding, sample size and the two women who dropped out.

Specification links:

AQA A-level Biology: aerobic respiration, including acetyl coenzyme A combining with a four-carbon molecule, the oxidation-reduction reactions of the Krebs cycle, and amino acids as respiratory substrates that enter the Krebs cycle (3.5.2); and synaptic transmission (3.6.2.2).

OCR A-level Biology A: the Krebs cycle, including the formation of citrate from acetyl CoA and oxaloacetate and its reconversion to oxaloacetate (5.2.2 e); the importance of the coenzymes NAD, FAD and coenzyme A (5.2.2 f); and the action of neurotransmitters at synapses (5.1.3 d). It also links to How Science Works on telling correlation from cause (HSW5) and evaluating methodology and evidence (HSW6).

Share this content:

Bryn Williams

Bryn has taught A-level Biology for over 20 years and has held management positions in education including Head of Biology. Bryn has been an Expert Examiner for A-level Biology for several years and is a member of the Royal Society of Biology.